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Acute angle closure 
A B S T R A C T   
Purpose: To report a case of Acute bilateral angle closure and Myopia following oral Cefixime therapy for 
pharyngitis. 
Observation: A 49-year-old man presented to the clinic with a history of aggravating ocular pain and blurry vision 
in both eyes from 5 days ago. He was under treatment with oral Cefixime 400 mg twice a day for acute bacterial 
pharyngitis since last week. His refractive error was − 3.75 and − 4.25 diopters in the right and left eye 
respectively. Intraocular pressure (IOP) was 32 mm Hg in the right eye and 40 mm Hg in the left eye. Slit lamp 
examination and gonioscopy showed shallow anterior chamber with 360◦ appositional angle closure. Ultrasound 
biomicroscopy revealed shallow anterior chamber, narrow angle, supraciliary effusion and anterior rotation of 
ciliary body in both eyes. With diagnosis of drug-induced acute angle closure, oral Cefixime was discontinued 
and eye drops Betamethasone every 4 hours, Cosopt and Brimonidine twice a day, and Atropine 1% twice a day 
were started. Few days after starting treatment all ocular symptoms and signs were resolved. 
Conclusions and importance: Systemic Cefixime can induce acute angle closure disease with myopic shift and 
elevated IOP secondary to supraciliary effusion and ciliary body rotation.   
Introduction 
Cefixime is one of the widely used antibiotics worldwide since its 
FDA approval in 1989.1 Its main mechanism of action is inhibiting the 
cell wall synthesis in bacteria. Cefixime is usually prescribed for un-
complicated urinary tract infections, otitis media, pharyngitis and 
tonsillitis, acute exacerbations of chronic bronchitis, and Gonorrhea 
(cervical/urethral).2,3 Systemic complications of Cefixime include but 
not limited to diarrhea, dyspepsia, nausea and rarely urticaria and 
Stevens-Johnson syndrome.4 To the best of our knowledge, acute angle 
closure disease and acute myopia secondary to oral Cefixime have not 
been reported so far. 
Case report 
49-year-old man presented to our clinic on April 2019 with ocular 
pain and blurry vision from 1 week ago. The past ocular and systemic 
diseases were all negative. He has been using Cefixime 400 mg capsule 
(CEFIXIME 400MG CAP, Farabi Pharmaceutical Company, Iran) twice a 
day from 1 week ago due to acute bacterial pharyngitis. On ocular 
examination, best corrected visual acuity (BCVA) of the right and left 
eyes were 20/30 and 20/20 respectively. The refractive error was − 3.75 
and − 4.25 diopters in the right and left eye respectively. He had never 
had a visual problem to use corrective glasses. Intraocular pressure 
measured by Goldmann applanation tonometer was 32 mm Hg in the 
right eye and 40 mm Hg in the left eye. 
Slit lamp examination in both eyes showed chemosis, mild cortical 
cataract and shallow anterior chamber (AC). In gonioscopy, there was 
360◦ appositional angle closure. Funduscopic examination showed pink 
and sharp optic disc with Cup/disc ratio of 0.4 in both eyes. Based on the 
history of the patient and ocular examinations, diagnosis of secondary 
acute angle closure disease induced by systemic medications was made. 
Ultrasound biomicroscopy was then performed which showed shallow 
anterior chamber, narrow angle, supraciliary effusion and anterior 
rotation of the ciliary body in both eyes. (Fig. 1). By considering the 
pathophysiology of the disease, oral Cefixime was discontinued and oral 
prednisolone 50 mg/day (PREDNISOLONE- FORT 50MG TAB, Abur-
aihan Pharmaceutical Company, Iran), eye drop Betamethasone 
(BETAMETHASONE DP 0.1% 5ML OPH DROP, Daroupakhsh Pharma-
ceutical Company, Iran) every 4 hours, eye drop Cosopt (COSOPT Drop, 
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Ophthalmic 2/0.05%,5 ml, Behestan Pharmaceutical Company, Iran) 
and Brimonidine (BRIMONIDINE DP 0.2% OPH DROP, Daroupakhsh 
Pharmaceutical Company, Iran) twice a day and eye drop Atropine 
Sulfate 1% (Atrin 1% OPH DROP, Sinadarou Labs Company, Iran) twice 
a day were prescribed. 
On the next day, the ocular symptoms were improved with 20% 
reduction in IOP and myopia in both eyes. After 5 days of starting 
medications, myopic shift, elevated IOP and supraciliary effusion were 
resolved completely in both eyes. Also refractive error reached to − 0.5 
diopter with BCVA of 20/20 in both eyes. In gonioscopy, angle was open 
in all quadrants with no signs of synechia formation. 
Discussion 
Cefixime is a third generation cephalosporin with chemical formula 
of C16H15N5O7S2⋅3H2O and molecular weight of 507.50 g/mol. It is a 
broad spectrum antibiotic active against gram-positive and gram- 
negative bacteria. This antibiotic is widely used in systemic infections 
but its use in the field of ophthalmology is very limited. In the European 
Union, intracameral Cefixime is utilized during the cataract surgery as a 
prophylaxis of postoperative endophthalmitis.5 There are no recognized 
ocular side effects related to Cefixime except for rare mild inflammation 
of ocular surface.6 
This is the first report of acute angle closure disease and acute 
myopia following the systemic use of Cefixime for acute pharyngitis. His 
past medical history was unremarkable for any specific diseases 
including hypertension and cardiovascular diseases. Additionally, he 
declared no history of any significant ocular diseases. Cefixime was the 
only drug that he had consumed in past few months. Hereby, induced 
myopic shift and supraciliary effusion was mainly contributed to 
Cefixime consumption. Although it seems that people with undetected 
narrow iridocorneal angle, hyperopia and positive family history of 
angle closure are more susceptible to this idiosyncratic reaction,7,8 but 
in our case, none of the factors mentioned above were observed. Few 
days after suspension of Cefixime and starting topical Cycloplegic, 
Cosopt and Brimonidine and oral prednisolone, all ocular manifestations 
were resolved. 
Overall, systemic medications can induce acute rise of IOP or 
glaucoma by 2 different mechanisms: the first is acute angle closure 
attack by pupillary block mechanism secondary to the anticholinergic or 
adrenergic properties of the drug. The second mechanism is non- 
pupillary block angle closure that occurs because of supraciliary or 
suprachoroidal effusion, anterior rotation of ciliary body and lenticular 
swelling. The first mechanism usually occurs on those cases with 
anatomical predisposition such as shallow anterior chamber, small 
anterior chamber volume and narrow or occludable angle. In our case, 
all the clinical and imaging findings were in favor of the second mech-
anism as a cause of the disease. The most common group of drugs with 
the potential to stimulate myopia and glaucoma attack is Sulfa-based 
drugs. Medications containing sulfa component include antibiotics (e. 
g. Trimethoprim-sulfamethoxazole, Sulfadizine, Sulfisoxazole, Dapsone, 
and Topical sulfa antibiotics), Rheumatologic drugs (e.g. Sulfasalazine, 
Probenecid, and Celecoxib), Sulfonylurea, Diuretics (e.g. Acetazol-
amide, Furosemide, Hydrochlorothiazide) and other drugs such as Su-
matriptan, Topiramate, Sotalol and Zonisamide.7,9 Additionally, some 
studies reported the same probable role for prostaglandin E2, Isotreti-
noin and Cefalium.10–12 By correct diagnosis, early treatment and dis-
continuing the responsible drug, all ocular findings will be reversible.13 
For the management of the secondary angle closure, topical cycloplegics 
(mostly topical 1% atropine or Homatropin), topical and systemic ste-
roids as well as aqueous suppressant (e.g. drop Beta blocker, adrenergic 
agents and Carbonic anhydrase inhibitors) are prescribed. Unfortu-
nately, many of these cases are wrongly diagnosed as primary angle 
closure attack and YAG laser PI is performed. There are some clinical 
points which help to differentiate between these two mechanisms such 
as simultaneous bilateral involvement and significant myopic shift 
which is induced mostly by systemic medications. 
In conclusion, systemic Cefixime can cause ciliochoroidal effusion, 
increased IOP, angle closure glaucoma and induced myopia. Although 
this complication has not been reported before but physicians should be 
aware of this rare side effect. 
Patient consent 
This report does not contain any personal identifying information of 
the patient. Additionally, a written consent was obtained from the 
Fig. 1. a and b; slit photos shows shallow anterior chamber of the right and left eye respectively. c and d; ultrasound biomicroscopy shows supraciliary effusion of the 
right and left eye respectively. . e and f; ultrasound biomicroscopy shows appositional angle closure and supraciliary effusion of the right and left eye respectively. 
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patient. 
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